ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that multiple...

Read More Details
Finally We wish PressBee provided you with enough information of ( ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year )

Also on site :

• Metal Ions: The Next Frontier in Diabetes Management?
• Starmer to send failed asylum seekers abroad - a year after Rwanda scheme scrapped
• Saudi Arabia and US reach consensus on ending the war in Gaza